AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9148337
Drug: Nifurtimox (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifurtimox (5 mg/kg/day for 30 days)
Trial: 8241095
Drug: pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 40 mg/d
Trial: 8241095
Drug: fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fish oil 6 g/d (equivalent to 3 g omega-3 fatty acids/d)
Trial: 8241095
Drug: combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined therapy of pravastatin 40 mg/d plus fish oil 6 g/d
Trial: 31881614
Drug: 1,4-Diaminobutane (1,4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,4-Diaminobutane (1,4 DAB) 0.8% cream applied once per day at night
Trial: 31881614
Drug: 1,4-Diaminobutane (1,4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,4-Diaminobutane (1,4 DAB) 0.8% cream
Trial: 31881614
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (cream base alone)
Trial: 26541842
Drug: sitagliptin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin plus insulin
Trial: 26541842
Drug: placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus insulin
Trial: 20510987
Drug: Motor imagery
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor imagery integrated into usual therapy
Trial: 18688620
Drug: Portal vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal vein infusion of 5-FU 500 mg/m² plus heparin for 24 hours for seven consecutive days plus mitomycin C 10 mg/m² on the first day
Trial: 18688620
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 5-FU 500 mg/m² plus heparin for 24 hours for seven consecutive days plus mitomycin C 10 mg/m² on the first day
Trial: 14687818
Drug: N-Butyl-2-Cyanoacrylate (cyanoacrylate)
RxNorm normalized name: N-(n-Butyl)deoxynojirimycin
DrugBank: Enbucrilate (DB12358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Butyl-2-Cyanoacrylate (cyanoacrylate) glue injection
Trial: 7631644
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg cocaine
Trial: 1544117
Drug: Lumpectomy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumpectomy followed by radiation therapy
Trial: 3899951
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil 40 mg three times daily
Trial: 14618045
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antiarrhythmic agents)
Trial: 31907186
Drug: Artesunate-Amodiaquine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-Amodiaquine (200 mg AS/540 mg AQ) plus Methylene Blue (325 mg)
Trial: 22206795
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg under fed conditions
Trial: 22206795
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg under fasted conditions
Trial: 22206795
Drug: Vandetanib 800
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vandetanib 800 mg
Trial: 22206795
Drug: Vandetanib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (various doses in Study A)
Trial: 22206795
Drug: Vandetanib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (all doses)
Trial: 12364632
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg CDP870 (n = 8)
Trial: 12364632
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg CDP870 (n = 8)
Trial: 12364632
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg CDP870 (n = 8)
Trial: 12364632
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment effect of CDP870 (0, 1, 5, 20 mg/kg)
Trial: 12364632
Drug: Open-label infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label infusion of 5 or 20 mg/kg CDP870 (n = 32)
Trial: 9327688
Drug: Injections before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections before 90 minutes (mean 2.46 ± 1.78; n = 94)
Trial: 9327688
Drug: Injections before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections before 90 minutes (mean 2.71 ± 2.42; n = 295)
Trial: 9327688
Drug: Injections before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections before 90 minutes (mean 2.53 ± 2.53; n = 184)
Trial: 9327688
Drug: Injections before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections before 90 minutes (mean 2.76 ± 2.03; n = 204)
Trial: 8452276
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg/kg bolus followed by infusion of 1 micrograms.kg‐1 x min‐1
Trial: 8452276
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg/kg bolus followed by infusion of 2 micrograms.kg‐1 x min‐1
Trial: 8452276
Drug: Midazolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.4 mg/kg bolus followed by infusion of 4 micrograms.kg‐1 x min‐1
Trial: 3725003
Drug: Amitriptyline, 50
RxNorm normalized name: Perphenazine-Amitriptyline, 50 mg-4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline, 50 mg
Trial: 23409601
Drug: Combination training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination training group (1 x 9 reps with 3-kg medicine ball, followed by 3 x 14 reps with water polo ball)
Trial: 23409601
Drug: Medicine-ball training
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine-ball training group (3 x 6 reps with 3-kg medicine ball)
Trial: 20634482
Drug: Concurrent-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent-adjuvant chemotherapy (CRT) with cisplatin (100 mg/m² every 3 weeks for three cycles) plus radiotherapy
Trial: 20634482
Drug: Concurrent-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent-adjuvant chemotherapy (CRT) with cisplatin plus radiotherapy
Trial: 20634482
Drug: Concurrent-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent-adjuvant chemotherapy (CRT)
Trial: 16473223
Drug: LASIK treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LASIK treatment (bilateral, same-day)
Trial: 16473223
Drug: Post-LASIK treatment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-LASIK treatment (surgical emmetropes)
Trial: 10502590
Drug: Dehydroepiandrosterone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dehydroepiandrosterone (50 mg orally each morning for four months)
Trial: 10502590
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for four months)
Trial: 8595540
Drug: Salmeterol, 50
RxNorm normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol, 50 microgram twice daily
Trial: 8595540
Drug: Disodium cromoglycate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate, 20 mg four times daily
Trial: 1955633
Drug: Cromolyn (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn (20 mg via nebulizer, three times per day)
Trial: 1955633
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (inhaled corticosteroid, dosage not specified, three times per day)
Trial: 28611102
Drug: Intramuscular gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular gentamicin and oral amoxicillin for 7 days at health posts
Trial: 21878034
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing (MI) prior to Cognitive Behavioural Therapy (CBT)
Trial: 15028439
Drug: Prophylactic protocol
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic protocol (40 mg mitomycin-C)
Trial: 15028439
Drug: Ablative protocol
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative protocol (80 mg mitomycin-C)
Trial: 11842896
Drug: G115 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G115 400 mg
Trial: 11842896
Drug: G115 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G115 200 mg
Trial: 11842896
Drug: G115 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G115 600 mg
Trial: 11842896
Drug: G115 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G115 200 mg and 400 mg
Trial: 9114912
Drug: Dilevalol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 400 mg
Trial: 2471287
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (about 840 mg, equivalent to 6 million Kallikrein inactivator units)
Trial: 1103273
Drug: Carbenoxolone 100
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone 100 mg three times daily
Trial: 1103273
Drug: Geranyl farnesyl
RxNorm normalized name: farnesyl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geranyl farnesyl acetate (Gefarnate) 100 mg three times daily
Trial: 31192869
Drug: Postoperative anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative anticoagulation (IV heparin or heparin with dextran)
Trial: 27434221
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitor sitagliptin
Trial: 21348806
Drug: liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.2 mg + glimepiride
Trial: 21348806
Drug: liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.8 mg + glimepiride
Trial: 21348806
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg + glimepiride
Trial: 14614218
Drug: Isoflavone extract
RxNorm normalized name: flaxseed extract 250 MG / soy isoflavones 250 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone extract (61.8 mg) for three months
Trial: 8750523
Drug: Ovarian irradiation
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian irradiation plus prednisone (R + P) 7.5 mg daily for up to five years
Trial: 8750523
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy (NT)
Trial: 8750523
Drug: Ovarian irradiation
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian irradiation with or without prednisone therapy
Trial: 1421933
Drug: Oral gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gentamicin (10 mg/kg body weight/day for five days)
Trial: 1421933
Drug: Oral gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gentamicin and placebo
Trial: 27377549
Drug: Medication Review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Review Tool
Trial: 21265353
Drug: Restricted fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted fluid resuscitation (no induction bolus, then LR 2 mL/kg/h)
Trial: 21265353
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid resuscitation (500 LR induction bolus, then LR 7 mL/kg/h x 1 h, then 5 mL/kg/h)
Trial: 18504252
Drug: Standard radiosensitised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiosensitised induction chemoradiotherapy (arm A) with cisplatin (90 mg/m(2) day 1) plus etoposide
Trial: 18504252
Drug: Daily radiosensitised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily radiosensitised induction chemoradiotherapy (arm B) with cisplatin (6 mg/m(2)/day) plus etoposide
Trial: 18504252
Drug: Daily radiosensitised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily radiosensitised induction chemoradiotherapy (arm B)
Trial: 15687942
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + clavulanic acid
Trial: 6365409
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion alone
Trial: 6365409
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion with prostaglandin E2
Trial: 6365409
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 administration alone
Trial: 31671873
Drug: Aromatherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy combined with music therapy
Trial: 28602779
Drug: Ceritinib 750
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 750 mg per day fasted
Trial: 28602779
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2)
Trial: 25989338
Drug: Briakinumab 200
RxNorm normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Briakinumab 200 mg
Trial: 25989338
Drug: Briakinumab 400
RxNorm normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Briakinumab 400 mg
Trial: 25989338
Drug: Briakinumab 700
RxNorm normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Briakinumab 700 mg
Trial: 10655024
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily
Trial: 16047460
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg twice daily
Trial: 21417971
Drug: Formaldehyde treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formaldehyde treatment of temporalis muscle fascia grafts
Trial: 21417971
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no formaldehyde treatment)
Trial: 19113796
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine and sertraline, mirtazapine, and nefazodone as pharmacologic therapy for depression in heart failure patients.
Trial: 19113796
Drug: Beta-blockers in
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers in patients with depression and heart failure.
Trial: 11574184
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) 0.625 mg alone for 30 days
Trial: 11574184
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + continuous combined medroxyprogesterone acetate (MPA) 2.5 mg/daily for 28 days
Trial: 11574184
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + cyclical MPA (10 mg o.d. from day 16 to day 28)
Trial: 9625845
Drug: Paclitaxel (TX)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (TX) 175 mg/m2 by 3 h i.v. infusion every 21 days
Trial: 8160217
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy and carotid endarterectomy
Trial: 3116132
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) for 9.7 +/- 1.1 days
Trial: 26599376
Drug: Aspirin intake
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin intake at 8.00 AM
Trial: 26599376
Drug: Aspirin intake
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin intake at 8.00 PM
Trial: 25611785
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment in the GLUCOLD trial
Trial: 16403243
Drug: Combined cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive behavioral therapy (CBT) and pharmacotherapy intervention
Trial: 16403243
Drug: Usual primary-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual primary-care treatment
Trial: 12602908
Drug: DCT 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCT 50 mg/m2 bimonthly schedule
Trial: 12602908
Drug: DCT 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCT 75 mg/m2 every 3 weeks (calibration arm)
Trial: 12602908
Drug: DCT 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCT 60 mg/m2 bimonthly schedule
Trial: 12602908
Drug: DCT 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCT 40 mg/m2 bimonthly schedule
Trial: 12602908
Drug: DCT 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCT 75 mg/m2 every 3 weeks
Trial: 9100679
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (three perioperative doses of cefazolin)
Trial: 31679753
Drug: Psychological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatments for depression
Trial: 27273710
Drug: SFC50 (salmeterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC50 (salmeterol xinafoate 50 μg/day and fluticasone propionate 100 μg/day)
Trial: 20566010
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin oral tablets once daily (GB)
Trial: 16481664
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (MTS) 10, 16, 20, and 27 mg applied in the morning for 9 hours
Trial: 9095512
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies in 'Other Blood Groups'
Trial: 8250363
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg midazolam orally and 0.2 mg sublingual buprenorphine (group 2)
Trial: 8250363
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg midazolam orally and 0.4 mg sublingual buprenorphine (group 3)
Trial: 8250363
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg midazolam orally (group 1)
Trial: 3879105
Drug: 24R,25 (OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24R,25 (OH)2D3 (10 micrograms daily)
Trial: 31074641
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of physician's choice (control)
Trial: 25538178
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg monotherapy (V)
Trial: 25538178
Drug: Vandetanib 100
RxNorm normalized name: vandetanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 100 mg plus gemcitabine (V/G)
Trial: 25538178
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus placebo (G/P)
Trial: 23161001
Drug: Yohimbine 16.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 16.2 mg
Trial: 23161001
Drug: Yohimbine 32.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 32.4 mg
Trial: 48347
Drug: Hydromorphone 1
RxNorm normalized name: HYDROMORPHONE 1MG/ML NS INJ 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 1 mg
Trial: 19238452
Drug: Simvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (5 mg for children ≤30 kg, 10 mg for children >30 kg, doubled for two additional months)
Trial: 16918945
Drug: Glucocorticoid plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid plus mineralocorticoid hormone replacement
Trial: 10911825
Drug: Stinging nettle
RxNorm normalized name: Stinging Nettle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stinging nettle leaf (Urtica dioica) applied daily for one week